4 insiders at Boston Scientific Corporation (BSX) reported open-market stock purchases totaling $9,839,693 in recent weeks, according to filings with the U.S. Securities and Exchange Commission. The largest reported purchase came from Mahoney Michael F (director, officer: Chairman, President & CEO), who acquired 186,240 shares at $48.33 on August 03, 2026.
Source: SEC Form 4. Option grants and tax-withholding sales are excluded.
| Date | Insider | Role | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|
| 2026-08-04 | Habiger David C | director | 140 | $48.59 | $6,802 | SEC Form 4 |
| 2026-08-03 | Habiger David C | director | 1,042 | $48.07 | $50,084 | SEC Form 4 |
| 2026-08-03 | Mahoney Michael F | director, officer: Chairman, President & CEO | 186,240 | $48.33 | $9,001,408 | SEC Form 4 |
| 2026-07-31 | LUDWIG EDWARD J | director | 5,000 | $45.48 | $227,400 | SEC Form 4 |
| 2026-05-20 | Pegus Cheryl | director | 1,770 | $56.49 | $99,987 | SEC Form 4 |
| 2026-05-20 | LUDWIG EDWARD J | director | 3,580 | $56.68 | $202,914 | SEC Form 4 |
| 2026-05-20 | Habiger David C | director | 2,250 | $55.92 | $125,819 | SEC Form 4 |
| 2026-05-19 | Habiger David C | director | 2,200 | $56.95 | $125,279 | SEC Form 4 |
Boston Scientific Corporation is a Healthcare company in the Medical - Devices industry. It carried a market capitalization of about $71.0B, with shares trading near $47.74.
This article is automated factual reporting of public SEC filings, for informational purposes only. It is not investment advice, nor a recommendation, offer or solicitation to buy or sell any security, and reflects no opinion on the company. Figures are drawn from filings believed reliable but are not guaranteed. Always verify against the primary SEC filing and consult a licensed professional. Investing can lose value, up to total loss.